Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 568

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 568
---
--|:--|:--|:-----|:--|:--|:--|:--|:--|:---------|:--|:----|:--|:--|
| Restructuring expenses | ​ | ​ | ​                               | $ | 707 | ​ | ​ | ​ | ​    | $ | — | ​ | ​ | ​ | ​        | ​ | N/A | ​ | ​ | ​ | ​                              | $ | 5,689 | ​ | ​ | ​ | ​    | $ | — | ​ | ​ | ​ | ​        | ​ | N/A | ​ | ​ |

**328

TABLE OF CONTENTS

For the three months ended September 30, 2024, restructuring expenses were $0.7 million, which were related to the additional workforce reductions in the third quarter of 2024. There were no restructuring expenses recorded during the three months ended September 30, 2023. For the nine months ended September 30, 2024, restructuring expenses were $5.7 million which were related to Cara’s strategic prioritization of NP in January 2024 and the resulting discontinuation of Cara’s NP program in June 2024, Cara’s exploration of strategic alternatives to maximize shareholder value, and the associated workforce reductions during the year. There were no restructuring expenses recorded during the nine months ended September 30, 2023. Other Income, Net**

| ​                 
 ​                 
 ​                 | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Three Months EndedSeptember 30, 
 2024                            
 Dollar amounts in thousands     |   |     |   | ​ | ​ | 2023 |   |     |   | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | ​        
 % change 
 ​        | ​ 
 ​ | ​    
 ​    | ​ 
 ​ | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Nine Months EndedSeptember 30, 
 2024                           
 Dollar amounts in thousands    |   |       |   | ​ | ​ | 2023 |   |       |   | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | ​        
 % change 
 ​        | ​ 
 ​ | ​    
 ​    | ​ 
 ​ | ​ 
 ​ 
 ​ |
|:------------------|:--|:--|:--------------------------------|:--|----:|:--|:--|:--|:-----|:--|----